Olix completes Phase 1b dosing for hair loss drug, moves toward Phase 2a
The advance in OLX104C comes as L'Oréal Group-backed Olix prepares a second-half launch of Uverna Hair Tonic and broadens its RNAi platform into metabolic and eye disease programs.